Sillajen explains Pexa-Vec trial failure – it was the rescue medsSouth Korean biotech Sillajen was hit hard last week when its oncolytic virus therapy Pexa-Vec failed a phase Share XSillajen explains Pexa-Vec trial failure – it was the rescue medshttps://pharmaphorum.com/news/sillajen-explains-pexa-vec-trial-failure-it-was-the-rescue-meds/
Immunotherapy arms race latest: Merck buys Viralytics for $394mBig pharma pays 160% premium for Australian biotech Share XImmunotherapy arms race latest: Merck buys Viralytics for $394mhttps://pharmaphorum.com/news/merck-co-buy-viralytics-cancer-killing-virus-394m/